(Press-News.org) A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms.
Bile acid diarrhoea (BAD) is a common cause of chronic diarrhoea that is estimated to affect one in 100 adults in western countries, but is often mistaken for irritable bowel syndrome (IBS) by doctors. Many patients are not diagnosed correctly and undergo repeated unnecessary tests.
The study at Imperial College London found that the drug obeticholic acid (OCA) could provide relief for patients with BAD. OCA is the first in a new class of drugs, farnesoid X receptor (FXR) agonists, and the response of the patients to OCA shows that abnormalities in the system it targets may be critical for this condition. The research is published today in the journal Alimentary Pharmacology and Therapeutics.
Professor Julian Walters, from the Department of Medicine at Imperial College London, who led the study, said: "Many doctors are totally unaware of bile acid diarrhoea, but it's more common than Crohn's disease and ulcerative colitis. When patients are correctly diagnosed, there are specific treatments that can help them, but many people find these current drugs are unpalatable.
"The condition often has a serious impact on patients' work and social lives, causing people to have up to ten watery bowel movements a day, often for many months, with an urgent need to go to avoid accidental incontinence."
BAD is caused by excessive secretion of bile acids, a component of bile that aids digestion. After bile is secreted into the intestine from the gall bladder, the bile acids are normally absorbed in the ileum, a part of the small intestine. But in BAD, excess bile passes into the colon and causes watery diarrhoea.
A hormone produced in the ileum, FGF19, regulates the production of bile acids in the liver, and previous studies found that patients with BAD have low levels of FGF19. OCA targets the receptors in the ileum that stimulate the production of FGF19.
The researchers tested OCA in three groups of patients: 10 with primary BAD, where the intestine is otherwise healthy; 10 with secondary BAD, where malabsorption can occur as a result of another disease such as Crohn's; and eight with other causes of chronic diarrhoea, who served as a control group. The patients, who were treated at Imperial College Healthcare NHS Trust, recorded their symptoms in a diary for two weeks before starting OCA treatment, for two weeks taking the drug daily, and two weeks afterwards. They also had blood tests at the start and end of the OCA treatment period.
Symptoms improved with OCA treatment in the primary BAD patients and some secondary BAD patients, but not in those with other causes of chronic diarrhoea. The treatment was generally well tolerated.
Professor Walters added: "This drug represents a new potential approach to treating BAD by restoring the levels of the FGF19 hormone and so controlling bile acid production in the liver. These early findings suggest that FXR agonists could be effective for treating patients with chronic diarrhoea. This is exciting and we need larger studies to confirm this."
INFORMATION:
The study was carried out in collaboration with Intercept Pharmaceuticals, Inc. which is developing OCA for a variety of chronic liver diseases. It was funded in part by the Bardhan Research and Education Trust and by the Broad Medical Research Program.
For more information please contact:
Sam Wong
Research Media Officer
Imperial College London
Email: sam.wong@imperial.ac.uk
Tel: +44(0)20 7594 2198
Out of hours duty press officer: +44(0)7803 886 248
Notes to editors:
1. Reference: J.R.F. Walters et al. 'The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.' Aliment Pharmacol Ther, 20 October 2014. doi:10.1111/apt.12999 http://onlinelibrary.wiley.com/doi/10.1111/apt.12999/abstract
2. About Imperial College London
Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 14,000 students and 6,000 staff of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.
Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve global health, tackle climate change, develop sustainable sources of energy and address security challenges.
In 2007, Imperial College London and Imperial College Healthcare NHS Trust formed the UK's first Academic Health Science Centre. This unique partnership aims to improve the quality of life of patients and populations by taking new discoveries and translating them into new therapies as quickly as possible.
http://www.imperial.ac.uk
Researchers at NYU Langone Medical Center conclude new drug in development may offer first alternative to standard chemotherapy for T-Cell Acute Lymphoblastic Leukemia.
Researchers at NYU Langone Medical Center and elsewhere say that blocking the action of an enzyme "switch" needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia.
An estimated quarter of the 500 U.S. adolescents and young adults diagnosed each year with this aggressive disease fail to respond to standard chemotherapy drugs that target cancer ...
Washington, D.C.— Hydrogen—the most abundant element in the cosmos—responds to extremes of pressure and temperature differently. Under ambient conditions hydrogen is a gaseous two-atom molecule. As confinement pressure increases, the molecules adopt different states of matter—like when water ice melts to liquid and then heats to steam. Thus far, at extreme pressures hydrogen has four known solid phases. Now scientists, including Carnegie's Alexander Goncharov, have combined hydrogen with its heavier sibling deuterium—which has an added neutron ...
This issue of Health Affairs was supported by CVS Health.
Do specialty drugs offer value that offsets their high costs?
James D. Chambers of Tufts Medical Center and coauthors conducted a cost-value review of specialty versus traditional drugs by analyzing incremental health gains associated with each. This first-of-its-kind analysis is timely because the majority of drugs now approved by the Food and Drug Administration are specialty drugs produced using advanced biotechnology and requiring special administration, monitoring, and handling—all of which result ...
Philadelphia, PA (October 20, 2014)–Promising new research in the area of hepatitis C (HCV) therapy that suggests more patients, including those with cirrhosis, will be cured from this common cause of potentially fatal viral liver disease; as well as a number of abstracts that advance understanding of the safety and effectiveness of fecal microbiota transplantation for Clostridium difficile, are among the highlights of the American College of Gastroenterology's (ACG) 79th Annual Scientific Meeting , which will be held this week in Philadelphia. More than 4,000 ...
DURHAM, N.C. – Scientists have developed new geochemical tracers that can identify hydraulic fracturing flowback fluids that have been spilled or released into the environment.
The tracers, which were created by a team of U.S. and French researchers, have been field-tested at a spill site in West Virginia and downstream from an oil and gas brine wastewater treatment plant in Pennsylvania.
"This gives us new forensic tools to detect if 'frac fluids' are escaping into our water supply and what risks, if any, they might pose," said Duke University geochemist Avner ...
CHICAGO – Oct. 20, 2014 – Using a tablet screening app could prove to be an effective method to aid in the effort to reduce the incidence of avoidable blindness in populations at high-risk for glaucoma with limited access to health care, according to a study released today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology. In this study, researchers from the University of Iowa, the University of Maryland, Johns Hopkins University, the University of Michigan and the Tilganga Eye Institute in Nepal used a free peripheral vision assessment ...
CHICAGO – Oct. 20, 2014 – Researchers have developed a fast and inexpensive way to make facial prostheses for eye cancer patients using facial scanning software and 3-D printing, according to findings released today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology. Their novel process can create more affordable prosthetics for any patients who have hollow sockets resulting from eye surgery following cancer or congenital deformities.
In the United States, more than 2,700 new cases of eye cancer are diagnosed each year, according ...
BUFFALO, N.Y. — One of the few studies to examine gender differences among patients with irritable bowel syndrome (IBS) has found that males with the condition experience more interpersonal difficulties than do females with the condition. The findings challenge what had been predicted by the University at Buffalo investigator and his colleagues.
The study, "Understanding gender differences in IBS: the role of stress from the social environment," is being presented during the Oct. 19 poster session at the American College of Gastroenterology (ACG) annual meeting in ...
Being depressed is depressing in itself and makes you feel even worse. That is one reason why it is so hard to break out of depressive conditions.
New research out of Queen's University offers a new approach to do just that. Nikolaus Troje (Psychology, Biology and School of Computing) along with clinical psychologists from the University of Hildesheim, Germany, have shown that walking in a happy or sad style actually affects our mood. Subjects who were prompted to walk in a more depressed style, with less arm movement and their shoulders rolled forward, experienced worse ...
A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of – and ahead of – its other antidepressant effects, in a National Institutes of Health trial. Within 40 minutes after a single infusion of ketamine, treatment-resistant depressed bipolar disorder patients experienced a reversal of a key symptom – loss of interest in pleasurable activities – which lasted up to 14 days. Brain scans traced the agent's action to boosted activity in areas at the front and deep in the right hemisphere of the brain.
"Our ...
